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ABSTRACT The activation of transcription factor NF-kB (nuclear factor-kB) plays a central role in the induction of many
inﬂammatory response genes. This process is characterized by either oscillations or stable induction of NF-kB nuclear binding.
Changes in dynamics of binding result in the expression of distinct subsets of genes leading to different physiological outcomes.
We examined NF-kB DNA binding activity in lipopolysaccharide (LPS)-stimulated IC-21 cells by electromobility shift assay and
nonradioactive transcription factor assay and interpreted the results using a kinetic model of NF-kB activation. Both assays
detected damped oscillatory behavior of NF-kB with differences in sensitivity and reproducibility. 3,4-Dichloropropionaniline
(DCPA) was used to modulate the oscillatory behavior of NF-kB after LPS stimulation. DCPA is known to inhibit the production
of two NF-kB-inducible cytokines, IL-6 and tumor necrosis factor a, by reducing but not completely abrogating NF-kB-induced
transcription. DCPA treatment resulted in a potentiation of early LPS-induced NF-kB activation. The nonradioactive transcription
factor assay, which has a higher signal/noise ratio than the electromobility shift assay, combined with in silico modeling,
produced results that revealed changes in NF-kB dynamics which, to the best of our knowledge, have never been previously
reported. These results highlight the importance of cell type and stimulus speciﬁcity in transcription factor activity assessment.
In addition, assay selection has important implications for network inference and drug discovery.
INTRODUCTION
Nuclear factor-kB (NF-kB) is a family of structurally related
and evolutionarily conserved proteins related to the proto-
oncogene c-rel. In mammals, the family of NF-kB proteins
includes Rel (cRel), RelA (p65), RelB, NF-kB1 (p50), and
NF-kB2 (p52) (1). Homo- and heterodimers of these NF-kB
proteins combine to form active and repressive complexes of
gene transcription. The p50/p65 heterodimer of NF-kB is the
most frequently studied and most abundant complex in cells
(2). In resting cells, NF-kB is maintained inactive in the
cytoplasm complexed with its inhibitors (IkBs), which exist
in three isoforms, IkBa,b, and e (2). Upon activation through
a variety of receptor signaling pathways, including the toll-
like receptor (TLR) 4 and tumor necrosis factor (TNF)
receptor family members, IkBs undergo phosphorylation,
ubiquitination and proteolytic degradation (1,3). Phospho-
rylation of the IkBs is regulated by a multisubunit kinase,
termed IkB kinase (IKK), which contains two catalytic
subunits, IKKa and IKKb, and a regulatory subunit IKKg
(4). Proteolytic degradation of IkBs allows for rapid trans-
location of free NF-kB from the cytoplasm to the nucleus.
While in the nucleus, active NF-kB binds to DNA and pro-
motes the transcription of multiple genes, including the
autoinhibitor IkBa. Newly synthesized IkBa enters the nu-
cleus, where it binds to NF-kB, thereby enhancing NF-kB’s
dissociation from the DNA and causing its reexportation
to the cytoplasm, where it joins the pool of inactive NF-kB
complexes (1). Continuous cycling of IkBa degradation
and resynthesis results in oscillations in NF-kB activity (5).
Moreover, due to the importance of aberrant activation of
NF-kB in a variety of diseases, more than 780 compounds
have been identiﬁed that modulate NF-kB activation (6).
As illustrated by efforts to recapitulate temporal regulation
of the NF-kB pathway using mathematical models, e.g., by
Hoffmann et al. (5), the dynamics of this process has been
the subject of intense scientiﬁc scrutiny (7). However, how
therapeutics modulate the dynamics of the activation of
NF-kB is still unknown.
Present in all body compartments, macrophages initiate an
innate immune response to bacterial pathogens through
phagocytosis, thereby eliminating them by the generation of
reactive oxygen and reactive nitrogen species (8,9). Macro-
phages also activate T lymphocytes by acting as a profes-
sional antigen-presenting cell and secreting cytokines, such
as IL-6 and TNF-a (10). These cytokines are important early
mediators of acute inﬂammatory responses contributing to
downstream lymphocyte activation (11,12). Due to their
importance in immune surveillance, macrophages provide a
highly relevant context for the study of NF-kB.
The effects of 3,4-dichloropropionaniline (DCPA) on the
immune response have been studied extensively, and its
ability to suppress various macrophage functions has been
characterized. It has been demonstrated that DCPA decreases
both the phagocytic activity of macrophages and their ability
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to generate both reactive oxygen and reactive nitrogen spe-
cies (13). The production of inﬂammatory cytokines such as
TNF-a, IL-1b, and IL-6 was also decreased (14,15). A study
of the effects of DCPA on the steady-state levels of NF-kB
activation demonstrated a decreased nuclear localization of
NF-kB accompanied by a reduced, but not entirely abro-
gated, binding to DNA (16).
DNA binding of activity transcription factor can be de-
termined by different methods. The electromobility shift
assay (EMSA) detects complexes of protein (e.g., NF-kB)
and 32P-labeled DNA containing transcription factor con-
sensus sequences migrating through a nondenaturing poly-
acrylamide gel (17,18). DNA-protein complexes will migrate
more slowly than unbound radioactive probe and are thus
visualized as discrete bands of radioactivity in the upper part
of an acrylamide gel image (19,20). This technique is labor-
intensive and requires radioactivity.
The nonradioactive transcription factor assay (NTFA)
technique employs the principle of EMSA, where protein/
DNA interaction is observed in an enzyme-linked immuno-
sorbent assay format (21–23). Active NF-kB is captured as it
binds to its nonradioactive DNA consensus sequence, which
has been immobilized on a streptavidin-coated plate. The
transcription factor that formed complexes with DNA is then
probed with speciﬁc primary antibody (anti-p65) followed by
HRP-conjugated secondary antibody and substrate detection.
This method makes possible the sampling of a larger number
of tests in a shorter period of time and does not require ra-
dioactive labeling.
This study explores the initial phase of NF-kB oscillatory
behavior induced in lipopolysaccharide (LPS)-stimulated
macrophages by means of two independent methods com-
monly used for quantifying the binding activity of transcrip-
tion factors. Immunosuppressant DCPA is used to modulate
NF-kB activity and is incorporated in the dynamic model to
demonstrate the changes in transcription factor activation.
METHODS
Cell culture, stimulation, and DCPA treatment
The murine peritoneal macrophage cell line, IC-21, was cultured in 5% CO2
at 37C to 80% conﬂuency in complete RPMI (cRPMI) (BioWhittaker,
Walkerville, MD). cRPMI consists of RPMI 1640 supplemented with 10%
fetal bovine serum (Hyclone, Logan, UT), L-glutamine (2 mM), penicillin
(100 U/ml), streptomycin (100 mg/ml), 2-mercaptoethanol (5 3 105 M),
and Hepes buffer (10 mM) (all obtained from Sigma-Aldrich, St. Louis,
MO). IC-21 cells were treated with 99% pure DCPA (ChemService, West
Chester, PA) and simultaneously stimulated with 1 mg/ml LPS phenol
(Sigma-Aldrich) extracted for various times.
The human T cell line, Jurkat clone E6-1, was cultured in 5%CO2 at 37C
in cRPMI. Jurkat cells were treated with 99% pure DCPA and simulta-
neously stimulated with plate-bound anti-CD3 and anti-CD28. Anti-CD3-
coated plates were prepared by adding 10 mg/ml mouse antihuman CD3
(Ancell, Bayport, MN) to the wells and incubating for 90 min at 37C, then
storing overnight at 4C. Before the addition of the cells, the unbound anti-
CD3 was aspirated out of the wells and the wells were washed three times
with sterile phosphate-buffered saline. Jurkat cells were diluted to 1 3 106
cells/ml in cRPMI, and DCPA was added to the cells. Next, the Jurkat cells
were added to the anti-CD3-coated wells and 2 mg/ml of anti-CD28 (Ancell)
was added to each well. Nuclear extracts were isolated after cells were in-
cubated for the appropriate times.
Appropriate concentrations of DCPA were dissolved in 100% ethanol
(Mallinckrodt Baker, Paris, KY) and added to cells at concentrations ranging
from 0 to 150 mM. The ﬁnal ethanol concentration added to all cultures was
0.1%; control cultures received equal concentrations of ethanol.
Nuclear extracts
IC-21 cells were plated at a concentration of 83 105 cells in 5 ml of cRPMI
in 60-mm dishes and incubated overnight at 37C 5% CO2. IC-21 cells
were then treated with either 0.1% ethanol or DCPA at concentrations of
25 mM, 100 mM, and 150 mM, and stimulated with 1 mg/ml LPS. IC-21
cells were washed with 2.5 ml ice-cold Dulbecco’s phosphate-buffered
saline (BioWhittaker) and lysed by adding 200 ml of a buffer (lysis buffer)
consisting of 10 mM Hepes, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM phenylmethylsulfonyl ﬂuoride, 1 mM dithiothreitol (DTT),
and 1mg/ml of the protease inhibitors leupeptin, antipain, chymostatin, and
pepstatin A (Sigma-Aldrich). IC-21 cells were scraped off the dishes and
lysates were transferred to microcentrifuge tubes. For the Jurkat cells, after
anti-CD3/anti-CD28 stimulation, the cells were harvested from the wells
by vigorous pipetting followed by centrifugation to pellet the cells. The
cells were washed with 2.5 ml ice-cold Dulbecco’s phosphate-buffered
saline and lysed by adding 200 ml of the lysis buffer. Once in the lysis
buffer, all cells were incubated on ice for 15 min. Then, 50 ml of 10%
NP-40 was added, samples were vortexed for 30 s, and the lysates were
pelleted by centrifugation for 30 s at 14,000 rpm at 4C. The supernatants
(cytoplasmic extracts) were collected and saved at 20C. Pellets were
resuspended in 30ml of 20 mMHepes buffer (400 mMNaCl, 1 mMEDTA,
1 mM EGTA, 1 mM phenylmethylsulfonyl ﬂuoride, 1 mM DTT, and
1 mg/ml of the protease inhibitors (see above)), vortexed, and incubated for
15 min on ice. The lysates were pelleted by centrifugation at 14,000 rpm for
5 min under the same conditions and the supernatants containing the nu-
clear fraction were stored at 70C. A total protein concentration for nu-
clear extracts was determined with Coomassie Plus Protein Assay Reagent,
as described by the manufacturer (Pierce, Rockford, IL).
Electrophoretic mobility shift assay
NF-kB consensus oligonucleotides (sc-2505, Santa Cruz Biotechnology,
Santa Cruz, CA) were labeled with g-32P-ATP (PerkinElmer, Boston, MA)
using a Ready-To-Go T4 polynucleotide kinase kit (Amersham Pharmacia
Biotech, Piscataway, NJ). Nuclear extracts, 5 mg/sample, were incubated
with 50,000 cpm of labeled probe and 1 mg/ml dI/dC for 30 min at room
temperature in 13 binding buffer (53 stock: 250mMNaCl, 50mMTris-Cl,
50% (v/v) glycerol, 5 mMDTT, 2.5 mMEDTA, adjusted to pH 7.6, stored at
20C) to allow formation of band-shift complexes. Next, complexes were
resolved from free probe in 5% polyacrylamide gels (13 TGE, 5% glycerol,
0.075% ammonium persulfate, 0.1% TEMED). Samples were electro-
phoresed at 125 V for 4 h, dried on Whatman 3MM paper, and placed on
PhosphoImage Screens for analysis with ImageQuant TL Software (Amer-
sham Pharmacia Biotech). The EMSA experimental results are reported as
the ratio of the intensity measured for a particular condition (i.e., time . 0)
relative to the intensity of NF-kB before treatment (i.e., time ¼ 0).
Transcription factor assay
Nuclear extracts, 5 mg/sample, were analyzed by a Chemicon Non-Radio-
active Transcription Factor Assay to determine NF-kB p65 DNA binding
activity, as described by the manufacturer (Chemicon International, Temec-
ula, CA). Brieﬂy, nuclear extracts were incubated for 2 h with biotinylated
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NF-kB consensus DNA sequences in a transcription assay buffer containing
sonicated salmon sperm DNA to allow the formation of protein/DNA
complexes. Next, NF-kB protein in the nuclear extracts bound to biotinylated
consensus sequences was immobilized to the streptavidin-coated plate, and
any unbound material was washed away. NF-kB protein was detected with
a speciﬁc rabbit anti-p65 antibody, followed by incubation with antirabbit
HRP-conjugated antibody detected by TMB/E substrate. Absorbance of the
samples was measured with a mQuant Universal Microplate Spectropho-
tometer (Bio-Tek Instruments, Winooski, VT). The NTFA experimental
results are reported as the ratio of the absorbance measured for a partic-
ular condition (i.e., time . 0) relative to the absorbance before treatment
(i.e., time ¼ 0).
NF-kB model development
The development of a mathematical model for NF-kB activation was shaped
by two primary considerations: 1), the design of experiments that minimize
potential sources of biological variability; and 2), the ability to uniquely
determine parameter values from replicate measurements. To quantify the
effect of DCPA on LPS-stimulated NF-kB activation, we focused on the ﬁrst
45 min after LPS stimulation (see Discussion). Although more detailed
mathematical models for NF-kB have been proposed in the literature (e.g.,
Hoffman et al. (5)), the experimental objectives of this study required the
development of a new mathematical model that has identiﬁable parameters
(see Appendix). This new model implicitly represents a series of biological
events that occur within the timeframe of experimental interest. The stimu-
lation of macrophages by LPS results in the activation of the TLR4 pathway
(24). The transduction of signals via TLR4 results in the activation of a series
of intermediate signaling proteins and ultimately in the activation of IKK.
The activation of IKK leads to the liberation of NF-kB from protein com-
plexes with IkB inhibitor proteins. Active NF-kB translocates to the nucleus,
where it initiates the transcription of various genes, including the IkB pro-
teins. Newly transcribed and translated IkB proteins reenter the nucleus and
deactivate NF-kB. Shown schematically in Fig. 1, the initial dynamics of
NF-kB activation after LPS stimulation is represented by the three chemical
kinetic equations
d½cN
dt
¼k13TLR43 11 a3 ½DCPA½DCPA1KDCPA
 
3 ½cN;
(1)
d½aN
dt
¼ k13TLR43 11 a3 ½DCPA½DCPA1KDCPA
 
3 ½cN k23 ½aN3 ½iN; (2)
and
d½iN
dt
¼ k33 ½aN k43 ½iN; (3)
where cN, aN, iN, andDCPA represent the concentrations of inactive NF-kB
in the cytosol, active NF-kB in the nucleus, IkBa, and DCPA, respectively.
TLR4 is a Boolean variable that is equal to 1 when the cells are stimulated by
LPS. As the IC-21 macrophages were continually exposed to LPS, TLR4 is
equal to 1 for all of the experiments studied. The dynamic change in NF-kB
in the cytosol is represented by Eq. 1, where the impact of IKK on liberating
NF-kB and transport to the nucleus is represented by a single parameter k1.
We postulate that DCPAmodulates the activation of NF-kBwith the strength
parameter a. A negative value for a signiﬁes that DCPA inhibits the acti-
vation of NF-kB, whereas a positive value indicates potentiation. The change
in active NF-kB in the nucleus is represented by Eq. 2, where the second term
represents the inactivation of nuclear NF-kB by IkBa. The dynamic
transcription, translation, reimport to the nucleus of the NF-kB inhibitor
protein, IkBa, in response to active NF-kB, and degradation is represented
by Eq. 3. Additional terms could be added to these three equations to account
for recycling of the NF-kB-IkBa complex to the cytosol. However, inclusion
of these additional terms did not improve the ﬁtness of the model within the
timeframe of experimental interest (data not shown). The initial normalized
concentrations of aN and iN were set equal to 1 and 0, respectively. The
estimates for the initial concentration of cN and parameters k1, a, k3, and k4
were determined using these three ordinary differential equations and
experimental measurement of active NF-kB in the nucleus. The half-
maximal inhibition constant, KDCPA, was assumed to be 5 mM based on
the study by Xie et al. (14). The rate constant for the deactivation of active
NF-kB in the nucleus, k2, was assumed to be equal to 0.015 conc1 min1.
These three ordinary differential equations were evaluated within MatLab
V7.1 (MathWorks, Natick, MA). Summed squared error between experi-
mentally measured and simulated values for active NF-kB in the nucleus was
used to determine goodness of ﬁt. Optimal values for the parameters were
selected using a genetic algorithm and are detailed in Table 1. Parameter
values were determined from the combined analysis of all DCPA conditions
using a single assay platform (i.e., there are two sets of parameters: uEMSA
and uNTFA). Conﬁdence intervals for the parameters were determined using
bootstrap resampling.
Bootstrap resampling: conﬁdence
interval estimation
Bootstrap resampling is an effective method for the estimation of conﬁdence
intervals of model parameters (25). Let us assume that the experimental
measurement of a dynamic system can be described by the equation
yexpðti;AjÞ ¼ ymodðti;ujÞ1ejðtiÞ; (4)
where yexp(ti, Aj) is the measured value at time ti using assay Aj, and uj is the
vector of model parameters for assay j that are constant with respect to time.
A mechanistic model of the dynamic system provides an estimate of the
expected biological response, ymod(ti, uj), at time ti, given the parameter
vector uj. The measurement error for a particular assay, or residual, is rep-
resented by ej(ti) and can be obtained at each time point, ti. The population of
ej(ti) determined from the data set is a representative sample of the variability
in observing this phenomena experimentally using a particular assay.
Analysis of the variance ensures that there are no systematic errors in the
residual population.
Experimentally, replication is used to establish signiﬁcance of an obser-
vation. Bootstrap resampling is a computational approach that creates syn-
thetic replicates drawn from the population of residuals. The residuals are
ﬁrst normalized based on the appropriate error model of the experimental
assay. Normalization is performed to ensure that the residuals are indepen-
dent of the dependent variables. Error models for each of the assays (NTFA
and EMSA) were based upon an analysis of the residuals. The statistical
FIGURE 1 Schematic diagram of the mathematical model developed to
represent the initial activation of NF-kB.
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signiﬁcance for the difference in the variance of residuals was estimated
using the ratio of variances as a test statistic. The test statistic was compared
against the F-distribution, where the degrees of freedom were determined
from the size of the two groups. A p value of ,0.05 was considered statis-
tically signiﬁcant. Synthetic sets of experimental replicates were created
using the following steps. First, optimal values for k1, k3, a, and the initial
value for cN were determined based upon the DCPA dose-escalation ex-
periments using either NTFA or EMSA. Second, expected values (ymod
(ti, uj)) were calculated using Eqs. 1–3 (the NF-kB model) and the set of
optimal parameters, using either uEMSA or uNTFA, for every measured ex-
perimental condition (yexp(ti, Aj)) to yield the residuals, ej(ti). The residuals
were normalized based upon the error model that corresponds to the par-
ticular assay. Finally, a large number (Nboot ¼ 3000) of synthetic data sets
(i.e., bootstrapped data sets) that replicate the original experimental protocol
were created by sampling, with replacement, from the population of resid-
uals. These resampled residuals are then combined with the expected values
(ymod(ti, uj)) to give new synthetic data sets. A new optimal set of parameter
values were determined for the NF-kB model that capture the synthetic
DCPA dose-escalation experiments. Each one of the bootstrap data sets
yields a novel set of values for k1, k3, a, and the initial value of cN. This
collection of optimal values provides an estimate of the 95% conﬁdence
intervals for k1, k3, a, and cN(t ¼ 0), shown in Table 1. The reported sig-
niﬁcance corresponds to the probability that the strength parameter a is
positive. The bootstrap approach provides a good estimate of the conﬁdence
intervals, comparable to those found with classical statistical techniques,
given a sufﬁciently large bootstrap sample (i.e., Nboot $ 1000) and data
sample (i.e., Ndata $ 30) (26). An alternative bootstrapping approach is to
resample directly from the population of biological replicates, instead of
from the population of residuals. Bootstrap resampling of the biological
replicates would require .30 replicates performed at each experimental
condition. In this study, each residual value was considered an independent
observation. Bootstrap resampling of the residuals was justiﬁed as the re-
siduals appeared to be randomly distributed around the expected values
within the biological replicates for each DCPA treatment conditions (data
not shown).
RESULTS
We ﬁrst wanted to characterize the dynamics of NF-kB ac-
tivation in macrophage cell line. As shown in Fig. 2, sus-
tained LPS stimulation of a mouse peritoneal macrophage
cell line, IC-21, resulted in damped oscillations in NF-kB
DNA binding activity. Over a period of 6 h, the dynamic
activation of NF-kB was quantiﬁed using an EMSA at the
indicated time points (Fig. 2 a). IC-21 macrophages were
treated with either ethanol (control) or 100 mM DCPA and
stimulated with LPS to induce active NF-kB DNA binding.
Both treatments demonstrated similar damped oscillations
graphically represented in Fig. 2 b (EtOH, solid line, open
circles; 100 mM DCPA, dashed line, plus signs). These
damped oscillations observed in macrophages are in variance
with the ﬁndings of Covert et al. (27), which demonstrate
sustained NF-kB activation after LPS stimulation in mouse
embryonic ﬁbroblasts. Although the EMSA measurements
shown in Fig. 2 are representative of the dynamic response in
IC-21 macrophages to LPS, signiﬁcant variability was ob-
served between replicates after the initial peak in NF-kB
TABLE 1 List of variables and parameters for NF-kB activation model
Name Deﬁnition Assay Value 95% CI Units
k1 NF-kB activation rate constant NTFA 0.0676 (0.0090–0.160) min1
EMSA 0.0686 (0.0104–0.265) min1
k2 NF-kB inactivation rate constant NTFA 0.0150 Assumed conc1 min1
EMSA 0.0150 Assumed conc1 min1
k3 Synthesis of NF-kB inhibitor rate constant NTFA 0.0041 (0.0020–0.0139) min1
EMSA 0.0089 (0.0009–0.0407) min1
k4 Degradation of NF-kB inhibitor rate constant NTFA 0.0005 (0.0005–0.0410) min1
EMSA 0.0017 (0.0003–0.282) min1
a Effect of DCPA on NF-kB activation NTFA 0.480 (0.021–1.53) Unitless
EMSA 0.119 (0.296–0.913) Unitless
KDCPA Half-maximum DCPA concentration NTFA 5 See (14) mM
EMSA 5 See (14) mM
cN Initial concentration of NF-kB in cytosol NTFA 53.0 (32.4–292) conc
EMSA 17.2 (8.99–88.2) conc
aN Initial concentration of active nuclear NF-kB NTFA 1 Assumed conc
EMSA 1 Assumed conc
iN Initial concentration of IkBa NFTA 0 Assumed conc
EMSA 0 Assumed conc
DCPA Concentration of DCPA NTFA 0–150 Experimental conditions mM
EMSA 0–150 Experimental conditions mM
TLR4 Stimulation via TLR4 (Boolean variable) NTFA 1 Experimental conditions Unitless
EMSA 1 Experimental conditions Unitless
Optimal values for initial conditions and parameters were determined using a genetic algorithm. Separate values were determined from dose-escalation
measurements obtained using EMSA or NTFA assays. Nonparametric bootstrapping using residual errors provided estimates of conﬁdence intervals. CI,
conﬁdence interval; conc, concentration.
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activation (data not shown). Moreover, observed variability
in amplitude of response and frequency of response inhibited
the ability to quantify the pharmacological effect of a par-
ticular mediator on the dynamics of NF-kB. Based on these
ﬁndings, we focused subsequent efforts on quantifying the
dynamics of NF-kB activation within the ﬁrst 45 min after
LPS stimulation.
Next, both EMSA and NTFA were used to replicate mea-
surements of active NF-kB in the nucleus at multiple time
points during the initial peak of DNA binding activity (0–45
min) in response to LPS stimulation. Fig. 3 a demonstrates
multiple replicates of this process using EMSA; for compar-
ison, Fig. 3 b represents the data obtained using NTFA. Both
methods demonstrated the initial peak of NF-kB activation,
which reached a maximum at 20 min, caused by rapid deg-
radation of IkBa inhibitor, and resulted in maximum DNA
binding. Subsequent diminishing of NF-kB binding activity,
triggered by a resynthesis of IkBa, is graphically displayed as
a decline of the curve. A mathematical model, shown sche-
matically in Fig. 1, incorporating these biochemical steps was
created to capture this dynamic behavior. Parameter values
that correspond to each of the assays are shown in Table 1.
The EMSA measurements obtained from the LPS-induced
macrophage cell line are compared with the mathematically
simulated EMSA response in Fig. 3 a (ethanol, solid lines;
150 mM DCPA, dashed lines). For comparison, data from
NTFA is compared with mathematically simulated NF-kB
activation dynamics in Fig. 3 b. The overall kinetics of the un-
derlying biological mechanism observed using the NTFA and
EMSA assays are in agreement. The results of the comparison
between the two assays revealed that the NTFA exhibits greater
sensitivity and reproducibility in measuring active NF-kB rel-
ative to the EMSA, as shown by the differences in dynamic
ranges observed during the control experiments.
To manipulate the dynamics of NF-kB oscillatory behav-
ior, a known immunosuppressant, DCPA, was introduced
FIGURE 2 Biochemical measurement of oscillations in LPS-stimulated
IC-21 macrophages persists after DCPA treatment. (a) Nuclear NF-kB DNA
binding activity was assessed by EMSA at the indicated times after sustained
stimulation with LPS (1 mg/ml). Macrophages were treated with either
ethanol (E) or 100 mM DCPA (D). (b) The speciﬁc NF-kB mobility shift
phosphoimage was quantiﬁed using ImageQuant and normalized to basal
levels. Control (s) and DCPA-pretreated (1) macrophages exhibit similar
damped oscillatory behavior. Each experiment was performed twice.
FIGURE 3 Modeling the potentiation by DCPA of the early activation of
NF-kB in IC-21 macrophages after LPS stimulation. The dynamic response
in nuclear NF-kB was measured using (a) EMSA and (b) NTFA. The active
NF-kB in the nucleus was measured after LPS stimulation and treatment
with 0mM (h ; n ¼ 8 for EMSA; n ¼ 3 for NTFA), 25 mM (s; n ¼ 2 for
EMSA; n ¼ 3 for NTFA), 100 mM (1; n ¼ 4 for EMSA, n ¼ 3 for NTFA),
and 150 mM (3, n ¼ 1 for EMSA, n ¼ 3 for NTFA) DCPA. The simulated
time courses of active NF-kB without and pretreated with 150 mM DCPA
are shown as solid and dashed curves, respectively.
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into the experimental system. IC-21 macrophages were
treated with three different doses of DCPA—25, 100, and
150 mM DCPA—and simultaneously stimulated with LPS.
To quantify the effect of DCPA on the dynamics of binding
activity, we focused on the initial peak of NF-kB activation
after LPS stimulation. Both assays were used to characterize
alterations in NF-kB binding activity by DCPA in response
to LPS stimulation, and experimental results from EMSA and
NTFA are shown in Fig. 3, a and b, respectively. Each dosage
of DCPA is graphically represented by a different symbol
(s, 25mM;1, 100mM;3, 150mM). The effect of DCPA on
the dynamic activation of NF-kB was represented in the
mathematical model by modulating the activation rate of
NF-kB in the cytosol, k1. The pharmacologic effect of DCPA
on the initial activation of NF-kB was quantiﬁed by the
strength parameter a. Using the EMSA parameter values
shown in Table 1, the simulated NF-kB response to LPS after
treatment with 150 mM DCPA was compared with the
EMSA results in Fig. 3 a. In a similar way, the simulated
NTFA measurements after DCPA treatment were compared
with the NTFA results in Fig. 3 b. Overall, the simulated
responses for both NTFA and EMSA showed agreement with
the experimentally measured values. In comparison, the sim-
ulated results showed that, compared to EMSA, NTFA is
more able to discriminate between macrophages treated with
DCPA and controls. These differences were a reﬂection of
the values of a estimated using NTFA versus those estimated
using EMSA. The results from both assays suggest that
DCPA potentiates the activation of NF-kB at the early time
points (0–45 min). Quantitatively, the NTFA results suggest
that DCPA increases the activation rate of NF-kB by 48.0%
(a ¼ 0.480). In contrast, the EMSA results suggest that
DCPA increases the activation rate by 11.9% (a ¼ 0.119).
One of the most important aspects of data analysis is the
determination of conﬁdence intervals for model parameters
that represent the data. A bootstrap resampling approach
applied to the residuals (ej(ti)) between the predicted (ymod
(ti, uj)) and measured (yexp(ti)) values was used to estimate
the conﬁdence intervals of the model parameters. Before
applying the bootstrap algorithm, we analyzed the population
of residuals in terms of underlying structure. The residuals
are assumed to have a Gaussian distribution with a zero mean
(i.e., ej(ti) 2 N(0, s2(ti, uj, l)). Generally, the variance of
residuals, s2(ti, uj, l), is a function of time, the model pa-
rameters, and a parameter vector that is unique to the variance
of assay j, lj. The underlying structure in the variance of the
residuals is sometimes referred to as the error model. Separate
error models were created for the EMSA and NTFA mea-
surements. In this study, we assume that the error model is a
linear function of the predicted value:
s
2ðti;uj;lÞ ¼ l1; j ymodðti;ujÞ1l2; j: (5)
The parameter l1,j quantiﬁes the variance that is proportional
to the underlying signal being measured for assay j. The l2,j
parameter quantiﬁes the contribution of a random noise dis-
tribution to the error model for assay j. Values for l1,j and l2,j
can be estimated by combining the error model with the
equation for the residuals (ej(ti) ¼ yexp(ti, Aj)  ymod(ti, uj))
and rearranging terms to yield
yexpðti;AjÞ ymodðti;ujÞ
ymodðti;ujÞ ¼L1i;j1L2i;j3
1
ymodðti;ujÞ; (6)
where L1i,j and L2i,j provide estimates of variance parame-
ters l1,j and l2,j for assay j. The lefthand side of Eq. 6
represents the normalized error values and is plotted against
y1mod in Fig. 4. As identiﬁed in Fig. 4, the normalized error
FIGURE 4 Analysis of the NTFA and EMSA residuals
to construct appropriate error models. The difference be-
tween experimental measurement (yexp) and simulated re-
sponse (ymod) of active nuclear NF-kB (residual error) after
LPS stimulation in IC-21 macrophages is shown as a func-
tion of y1mod: EMSA measurements are shown as circles
and NTFA measurements as squares. The residual errors are
normalized by the simulated response. EMSA residuals with
y1mod. 0:2 were assigned to EMSA Group 2, and remaining
residuals were assigned to EMSA Group 1. Similar grouping
was applied to the NTFA residuals. Variances for each group
are shown in the ﬁgure. The difference in variance between
NTFA groups was not signiﬁcant, whereas the EMSA groups
exhibited signiﬁcant differences in variance (p , 0.05).
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values were empirically clustered into two groups based on
their respective values of y1mod: The variances of the two
groups for each assay are labeled in Fig. 4. The variance
compared between the high and low NTFA groups was not
statistically signiﬁcant, whereas the difference between
the EMSA groups was signiﬁcant (p , 0.05). These results
suggest that l2 ¼ 0 for the NTFA error model and that the
residuals are proportional only to the underlying signal
(ymod). In contrast, the variance in the EMSA measurements
is proportional to the underlying signal and contains contri-
butions from random noise.
Given this analysis of the residuals for the NTFA and
EMSA measurements, we constructed a bootstrap sample
population using the following error models:
eNTFAðtiÞ ¼ yexpðti;AjÞ ymodðti;uNTFAÞ
ymodðti;uNTFAÞ ; (7)
eEMSAðtiÞ ¼ yexpðti;AjÞ ymodðti;uEMSAÞ: (8)
The bootstrapped sample populations were used to provide
estimates of the conﬁdence intervals associated with the
model parameters. The 95% conﬁdence intervals for the
model parameters are shown in Table 1. We are particularly
interested in the conﬁdence intervals associated with the
strength parameter, a. Based upon bootstrapping of the
EMSA residuals, the 95% conﬁdence interval for the strength
parameter a spans the range 0.296–0.913 (p , 0.2). In
contrast, the 95% conﬁdence interval for the strength param-
eter a based on the NTFA residuals spans 0.021–1.53 (p ,
0.02). The other estimated parameters (k1, k3, and cN)
exhibited wider conﬁdence intervals from the EMSA results
compared to the NFTA results (e.g., O(101.6) for EMSA k3
versus O(100.8) for NTFA k3). Differences in the size of the
conﬁdence intervals indicate the differences in signal/noise
ratios for these two assays.
To test the predictive power of the mathematical model, we
also studied the inﬂuence of DCPA on NF-kB activation in a
human T cell line, Jurkat clone E6-1 (Fig. 5). Jurkat cells
were treated with either ethanol (squares) or 100 mM DCPA
(1) and cocultured with plate-bound anti-CD3 and anti-
CD28 to activate NF-kB. The extent of active NF-kB DNA
binding was measured using the NTFA. Activation of NF-kB
in Jurkat cells was delayed compared to LPS-stimulated IC-
21 macrophages. Due to the time delay associated with the
activation of NF-kB, the start of the simulation occurred 24
min after the Jurkat cells were exposed to anti-CD3/CD28.
As the pathways leading to NF-kB activation after anti-CD3/
CD28 stimulation (29) are different from LPS-induced acti-
vation (30), the ethanol control experiment (squares) was
used to adjust the parameters associated with the initial
concentration of inactive NF-kB in the cytosol (cN¼ 19) and
the NF-kB activation rate constant (k1 ¼ 0.015 min1). All
other parameters remained as speciﬁed in Table 1. The pre-
dicted response in NF-kB activation after exposure to 100 mM
DCPA (dotted line) is comparedwith the ethanol control (solid
line).
DISCUSSION
The combined experimental and simulation results using IC-
21 cells, a mouse macrophage cell line, suggest that DCPA
potentiates the early activation of NF-kB by 48.0%. In con-
FIGURE 5 Prediction of the DCPA potentiation of early activation of NF-
kB in Jurkat cells after stimulation with plate-bound anti-CD3 and anti-
CD28. (a) NF-kB activation through the T cell receptor involves different
membrane proximal signaling events compared to activation through the
toll-like receptor 4 (TLR4) signaling pathway. These two signaling path-
ways act through TRAF6 to activate the IkB-NF-kB signaling module. (b)
Nuclear NF-kB was assayed by NTFA at the indicated times after stimu-
lation with plate-bound anti-CD3 and anti-CD28 and treatment with 0 mM
(h) and 100 mM (1) DCPA. Two parameters (k1 and cN) of the mathe-
matical model were calibrated to the ethanol control results, providing a
prediction of the 100 mM DCPA results. The simulated time courses of
active NF-kBwithout and pretreated with 100 mMDCPA are shown as solid
and dashed curves, respectively. Each experiment was performed six times.
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trast, the EMSA results suggest that DCPA increases the
activation rate by 11.9% (a¼ 0.119). The potentiation of NF-
kB activation by DCPA was also conﬁrmed using the NTFA
in a human T cell line, Jurkat clone E6-1. These results seem
counterintuitive, as we have previously reported that 66 mM
DCPA resulted in an 80% reduction in IL-6 mRNA and
a 50% reduction in TNF-a mRNA after stimulation with
10mg/ml LPS (14). This suppression in mRNA resulted in an
inhibition of IL-6 production by 60% and TNF-a production
by 50%. However, the stabilities of IL-6 and TNF-a mRNA
were not affected by DCPA, which suggests that DCPA
modulates cytokine production speciﬁcally at the pretran-
scriptional level, as inhibition of the IkB proteins would
change the dynamics of NF-kB.
In particular, the dynamic resynthesis of the IkB inhibitor
proteins after the initial activation induces oscillations in NF-
kB (5). Conceptually, potentiating the activation of NF-kB
by DCPA would cause an increase in the resynthesis of IkB
proteins. This proportional increase in IkB proteins would
cause a more rapid reduction in active NF-kB, thus under-
shooting the concentration of active NF-kB in the nucleus
compared to the control experiment. In Fig. 3, this under-
shoot was apparent at 40 min, where the nuclear NF-kB in
DCPA-exposed cells was lower than the ethanol control. If,
on the other hand, DCPA inhibited the resynthesis of IkB
proteins, the level of inducible NF-kB would increase after
the initial rise (31), and gene expression would also increase.
Such a concomitant increase in gene expression is inconsis-
tent with prior studies (14). Further evidence supports our
hypothesis that DCPA modulates the activation of NF-kB at
the pretranslational level, as similar effects on NF-kB acti-
vation were observed in LPS-stimulated mouse IC-21 mac-
rophages and in human Jurkat T cells stimulated through the
T cell receptor (compare Fig. 3 b with Fig. 5). LPS activates
NF-kB in IC-21 macrophages via the MyD88 pathway as-
sociated with TLR4 (30). In contrast, activation of NF-kB
by stimulating the T cell receptor in Jurkat cells requires the
recruitment of multiple signaling proteins to the central zone
of the supramolecular activation cluster, leading to protein-
kinase-C-controlled activation of NF-kB (29). These two dif-
ferent signaling pathways converge at the polyubiquitin ligase
tumor necrosis factor receptor-associated factor 6 (TRAF6)
(32,33). TRAF6 in turn activates IKK, which facilitates the
degradation of the IkB inhibitory proteins. Collectively, these
observations suggest that DCPA differentially regulates NF-
kB-response genes via the IkB-NF-kB signaling module
through a yet undeﬁned pretranslational mechanism.
NF-kB regulates the inducible expression of a wide range
of immune and inﬂammatory response genes (34). As a re-
sult, NF-kB is one of the most studied molecules in the area
of signal transduction. Because of the complex nature of bio-
logical systems, the study of NF-kB is important for two rea-
sons. First, the objective of biomedical research is to identify
biochemical mechanisms that underpin the biological response
to stimuli. Second, biomedical research aims to develop strat-
egies that modulate aberrant biochemical mechanisms to revert
to a pathogenic state. In both cases, biological assays provide
avenues for observing cellular response after biochemical in-
terrogation.
One of the most important aspects in the design of a bio-
logical assay is selecting a physiologically relevant context.
We ﬁrst observed damped oscillations in active NF-kB in
macrophages after LPS stimulation. This observation is in
contrast to other published studies examining the dynamic
activation of NF-kB after LPS stimulation. In particular,
Werner et al. observed that in ﬁbroblasts the initial activation
of NF-kB by 0.1 mg/ml LPS was not rapid but depended on
autocrine feedback via the TNF-a pathway (35). Covert et al.
observed that 0.5 mg/ml LPS induced stable NF-kB activa-
tion through a combination of MyD88-dependent and
MyD88-independent pathways (27). In Fig. 6, we compare
our results to the results of Werner et al. (35) and Covert et al.
(27). The initial rates of NF-kB activation are similar in those
studies, which used mouse embryonic ﬁbroblasts. We ob-
served amuch higher initial rate of activation using 1.0mg/ml
LPS. This higher activation rate may be attributed to the in-
creased expression of CD14 in macrophages compared to
ﬁbroblasts and/or increased stimulant. Cellular response to
LPS is mediated by the TLR4 pathway (24). CD14, an ac-
cessory cell surface protein, interacts with TLR4 to increase
the sensitivity to LPS 1000-fold (36) and facilitates the robust
response to LPS.Moreover, as highlighted in Fig. 5 b, NF-kB
activation exhibits different dynamics after T cell receptor
stimulation in Jurkat cells than through the TLR4 pathway in
IC-21 macrophages. Variations in the initial rate of activation
of NF-kB reﬂect inherent differences in the efﬁcacy of sim-
ilar signaling pathways in different cell types that exist before
stimulation. Thus, the cellular context plays an important role
FIGURE 6 The dynamic activation of NF-kB in macrophages compared
with results of prior studies using ﬁbroblasts. Nuclear NF-kB was assayed
by EMSA at the indicated times after persistent stimulation with 1 mg/ml
LPS in macrophages in this study (h, n ¼ 8, values reported as average 6
95% conﬁdence interval), 0.5 mg/ml LPS in ﬁbroblasts, demonstrated by
Covert et al. (27) (s); and 0.1 mg/ml LPS in ﬁbroblasts, demonstrated by
Werner et al. (35) (3).
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in determining the contribution of a particular signaling
pathway on the dynamic behavior of NF-kB activation.
Chemical manipulation of NF-kB binding activity with
immunosuppressant DCPA resulted in earlier activation of
the initial peak observed during the ﬁrst 45 min after LPS
stimulation. This earlier activation might result in altered
frequency of the oscillations, which in turn will change the
transcriptional regulation of some genes. Changes in number,
period, and amplitude of oscillations were observed by
Nelson at al. (37) in HeLa cells continuously stimulated with
TNF-a. Furthermore, the transcription of NF-kB target genes
was dependent on persistence of oscillations. Nelson et al.
(37) also suggest that changes in oscillation could have
functional consequences for NF-kB signaling in response to
different stimuli. Therefore, inhibition of NF-kB-inducible
cytokines TNF-a and IL-6 observed in DCPA-treated cells at
the later time points (12 and 24 h after sustained LPS stim-
ulation) may be a result of the early potentiation of NF-kB
activation caused by a shift in oscillatory behavior.
An additional consideration in the design of a biological
assay is how to observe a cellular response. Observed vari-
ability in measured data is due to technical variation (e.g.,
error in measurement) or biological variation (e.g., cellular
heterogeneity, asynchrony, or stochasticity). Implicitly, de-
sign of the experimental protocol is intended to limit the
contributions of biological variation by selecting cellular
systems that exhibit favorable characteristics. A survey of the
literature suggests experimental conditions that can reduce
natural sources of biological variation. In the study by
Lipniacki et al. (38), stochastic simulations revealed that the
dynamics of the initial peak is independent of the number of
NF-kB molecules. Similarly, Nelson et al. demonstrated that
the dynamics of the initial peak were similar among cells
expressing ﬂuorescently labeled RelA (37). Collectively,
these studies and our own data suggest that by focusing on
the ﬁrst 45 min after LPS stimulation, natural sources of bi-
ological variability can be minimized.
In contrast, the contribution of technical variation has re-
ceived little attention. Moreover, the experimental tools of
molecular biology have been criticized with regard to quality
(39,40). Over the years, biochemical assays with improved
sensitivity have been developed (23). Yet, as we have shown
herein, technical variation can be attributed to multiple
sources. Improved sensitivity alone is an insufﬁcient criterion
to conﬁrm improvement of the information context of an
assay. If the technical variation is associated solely with the
magnitude of the signal, there will be no meaningful differ-
ence in the information extracted regarding cellular response
using either assay. However, when an assay, such as the
EMSA discussed here, exhibits a higher contribution of
random noise, pharmacologically signiﬁcant modulation of
cellular response and insight into underlying biological mech-
anisms can be masked. Thus, an assay such as the NTFA,
which has a greater signal/noise ratio, affords a clearer window
into fundamental cellular behavior. The importance of devel-
oping biological assays that exhibit improved signal/noise
ratios is highlighted by our study of the potentiation of NF-kB
activation by DCPA.
Although much effort has focused on identifying the dy-
namic phenomena associated with the activation of NF-kB,
we focused our efforts on understanding how these dynamic
phenomena can be modulated for therapeutic aims. After our
investigations into the impact of DCPA on the dynamic
modulation of NF-kB activation within a mouse peritoneal
macrophage cell line and a human T cell line, we have come
to the following three conclusions. First, the dynamic be-
havior of NF-kB in response to stimuli is dependent on cell
type and developmental stage. Second, DCPA potentiates
early activation of NF-kB, yet suppresses inﬂammatory gene
expression. Extraction of this counterintuitive behavior could
only be achieved through the use of a mechanistic model
that encoded the relevant biochemical events. Furthermore,
ascribing signiﬁcance to parameter values derived from a
mechanistic model must include parameter identiﬁability
considerations and the analysis of multiple biological repli-
cates. Finally, nonradioactive transcription factor assays have
a signal/noise ratio superior to that of electromobility shift
assays for observing cellular NF-kB response.
APPENDIX: PARAMETER IDENTIFICATION
An important aspect of sensitivity analysis is identiﬁcation of model
parameters that can be uniquely determined from the available data. A priori
identiﬁability is one approach to selecting identiﬁable parameters given
unlimited information about the modeled system (41,42). This assessment of
parameter identiﬁability is intimately linked to the sensitivity of the model
results to changes in parameter values. Local sensitivity analysis is deﬁned as
the relative change in model variables (yj) in response to a perturbation of the
TABLE 2 Correlation coefﬁcients of model parameters and initial concentration of NF-kB in cytosol
Correlation coefﬁcient k1 k2 k3 k4 a KDCPA cN (t ¼ 0)
k1 1 0.391 0.391 0.488 0.690 0.687 0.677
k2 0.391 1 1 0.950 0.302 0.289 0.348
k3 0.391 1 1 0.950 0.302 0.289 0.348
k4 0.488 0.950 0.950 1 0.374 0.368 0.143
a 0.690 0.302 0.302 0.374 1 0.999 0.506
KDCPA 0.687 0.289 0.289 0.368 0.999 1 0.520
cN (t ¼ 0) 0.677 0.348 0.348 0.143 0.506 0.520 1
Signiﬁcantly correlated parameters (p , 0.05) are highlighted in bold.
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model parameters (ki) around a local optimum (43). The resulting sensitivity
function is deﬁned as
SijðtÞ ¼ ki
MAXðyj;ðtÞÞ3
@yjðtÞ
@ki
; (A1)
where the partial derivative values are scaled by the parameter value and the
maximum value of the model variable during the simulation. In practice,
the sensitivity function is approximated by obtaining the sensitivity mea-
sure, Sij, at a set of discrete time points, tk, and experimental conditions,
[Cn]n. In addition, measurements of only a subset of the model variables
may be obtained experimentally. A reduced sensitivity matrix (M) is then
constructed using a subset of the sensitivity measures ðSijˆðtk;CnnÞÞ such that
M¼ ½Sijˆðt1;Cn0Þ; . . . ;Sijˆðtk;Cn0Þ;
Sijˆðt1;CnnÞ; . . . ;Sijˆðtk;CnnÞT: (A2)
A set of correlation coefﬁcients betweenmodel parameters is calculated from
M. Parameters that are locally identiﬁable have correlations with all other
parameters between 1 and11. Parameters that are not locally identiﬁable,
termed a priori unidentiﬁable, have correlations of exactly11 or 1 with at
least one other parameter.
The identiﬁability of the model parameters and initial concentration of
NF-kB in cytosol (cN (t ¼ 0)) were calculated using the NF-kB model
described in Eqs. 1–3. A combined sensitivity matrix was constructed from
sensitivity values obtained from simulations with 0 and 100 mMDCPA over
a period of 50 min after LPS stimulation. This combined sensitivity matrix
was reduced by assuming that the concentration of active NF-kB in the
nucleus ([aN]) was the only experimentally observable variable in the model.
We are particularly interested in the conﬁdence intervals associated with the
strength parameter a. The correlation coefﬁcients listed in Table 2 demon-
strate that estimates of the strength parameter a are unique if KDCPA is
speciﬁed as 5 mM, as determined previously (14).
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